New Directions With PARPis
New Directions With PARP Inhibitors in Pancreatic Cancer

Released: February 21, 2022

Expiration: February 20, 2023

Eileen O Reilly
Eileen O Reilly, MD
Naureen Starling
Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Activity

Progress
1
Course Completed

In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP,  discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

  • Current treatment landscape and testing in the United States vs the United Kingdom  
  • Testing for molecular subgroups beyond BRCAm
  • Using PARP inhibitors in earlier stages of the disease
  • Learning from other cancers, such as prostate, breast, and ovarian